Satellos Bioscience Inc. (MSCL)
TSX
Real-time Data
01:30 PM
Day's Range
10.5652 wk Range
7.56Overview - MSCL - Satellos Bioscience Inc.
Key Statistics
Valuation
Enterprise Value
281.64M
P/E (Trailing)
‪2.33‬
P/E (Forward)
‪-6.78‬
PEG Ratio
‪0.04‬
Price / Book
‪3.05‬
EV / EBITDA
‪-5.58‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-41.89%‬
Return on Equity
‪-70.44%‬
Ownership
Shares Outstanding
20.83M
Float
18.01M
Held by Insiders
‪6.36%‬
Held by Institutions
‪49.70%‬
Price stats
Beta
‪1.14‬
50-Day Avg
‪13.19‬
200-Day Avg
‪11.52‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
3 analysts
Average price target
‪CA$ 17.67‬Market Cap - MSCL - Satellos Bioscience Inc.
Peers - MSCL - Satellos Bioscience Inc.
Peer Comparison
Compared with companies in Biotechnology listed on TSX.
- MSCLTSXSatellos Bioscience Inc.265.20MMarket Cap+36.64%52-week change2.34P/E (Trailing)‪0.00%‬Profit Margin
- APMTSXAndean Precious Metals Corp.908.95MMarket Cap-40.33%52-week change5.50P/E (Trailing)‪26.46%‬Profit Margin
- AIMTSXAimia Inc.238.82MMarket Cap-15.13%52-week change7.08P/E (Trailing)‪5.24%‬Profit Margin
- BCTTSXBriaCell Therapeutics Corp.52.54MMarket Cap-148.51%52-week change-0.14P/E (Trailing)‪0.00%‬Profit Margin
- APLITSXAppili Therapeutics Inc.661.83KMarket Cap-500.00%52-week change-0.17P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - MSCL - Satellos Bioscience Inc.
About
Satellos Bioscience Inc. is a clinical-stage biotechnology company focused on developing therapies for degenerative muscle diseases. Satellos Bioscience Inc. works in regenerative medicine, using its proprietary MyoReGenX platform to study muscle stem cell biology and identify approaches that may restore the body’s…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
